Brain Science
Breakthroughs:

Innovative Therapies for Mental Illness

Building a Better Future with Our Treatment Portfolio


Our Pipeline


We are dedicated to developing innovative solutions for neuropsychiatric disorders. With a strong focus on neuroscience, we have an exciting pipeline of novel treatments that have the potential to revolutionise the way we approach mental wellness.

From cutting-edge brain science to advanced technology and a diverse pipeline, we're dedicated to finding new and better ways to support those struggling with mental health challenges. With a commitment to advancing the field and improving patient outcomes, we're poised to make a real difference in the lives of millions.

Depression treatment, Psychiatric disease, Novel drugs
neuroscience behavioural reviews publication
There is a dire need for novel therapies

Treatment resistant depression:

A multi-scale, systems biology approach, Neuroscience & Biobehavioral Reviews, Volume 84,2018, Pages 272-288.

Numerous Mental Conditions

Diverse drug targets: autism, stress, anxiety, psychiatric disorders, addiction, memory loss, Prader-Willi syndrome. Tackling significant unmet needs in mental health where traditional drug therapies often fall short, fostering innovation in treatment approaches.

Need for Effective Treatments

Pressing unmet needs in mental health call for innovative solutions. Current drugs often lack efficacy. Non-drug approaches explore promising alternatives to enhance the lives of individuals facing various neuropsychiatric challenges.

Our Focus Areas

At our company, we are focused on addressing these unmet needs by developing new treatments for autism, addiction, pain, depression, and more. Pioneering novel treatments, we address unmet needs in mental health therapeutics.

Our Lead Products

A balanced pipeline

Our groundbreaking solution for Treatment-Refractory Depression (TRD). Selegiline TTS, in its skin-patch form, effectively elevates key neurotransmitters - dopamine, norepinephrine, and serotonin - in the brain. This innovation removes the food interaction issues associated with oral dosing, ensuring patient safety and convenience.

Additionally, our focus extends to the remarkable potential of oxytocin, a key neuro-mediator involved in emotions, attachment, euphoria, and pain control. Overcoming the challenge of blood-brain barrier penetration, Occentis, our subsidiary, is set to revolutionise mental health treatments with novel drug candidates that are agonists of the oxytocin receptos. These drug candidates exhibit promise across a spectrum of mental health indications, including Autism, Alcohol and Opioid addiction withdrawal, Neuropathic pain, Depression, PTSD, and Prader-Willi Syndrome. With a proven track record and a natural formula, our approach combines innovation and comprehensive solutions to address unmet needs in mental health.

Neurentis is proud to announce our groundbreaking AI-driven drug discovery initiative, aimed at developing novel antidepressants. Leveraging the unparalleled computational power of Frontier, the world's fastest supercomputer, and our strategic collaboration with Netellis, we are poised to transform the treatment landscape for depression, including Treatment-Resistant Depression (TRD). This advanced approach allows us to screen billions of molecules, identify optimal drug candidates, and accelerate the discovery process. Our commitment to innovation ensures we remain at the forefront of mental health solutions, providing hope and improved outcomes for patients worldwide.

The potential to be a Safe and Effective Approaches to CNS Diseases

Scientific Breakthroughs

Mental health treatment

Our innovative patch offers a game-changing approach to resistant depression, bypassing food interactions and hepatic metabolism associated with oral medication. Furthermore, our pioneering oxytocin agonists delve into the uncharted potential of neuro-mediation in the brain, promising relief for a spectrum of mental health conditions. Our portfolio is complemented by Neurobiomod™, a natural formula that provides support.

New treatment for resistant depression
Multiple approaches

innovative solutions

innovative treatment for mental health
novel drugs for the central nervous system

Our oxytocin agonist program is a testament to our commitment to pioneering mental health solutions. Oxytocin, a remarkable neuro-mediator, is traditionally challenging to use as a drug due to its limited ability to penetrate the blood-brain barrier. However, our novel oxytocin agonists have successfully overcome this obstacle, represent breakthroughs in mental health treatments. This innovative approach, backed by extensive research and a strategic partnership with the CNRS, opens doors to addressing a wide range of mental health conditions, including Autism, Alcohol and Opioid addiction withdrawal, Neuropathic pain, Depression, PTSD, and others.

Our selegiline patch, offers a groundbreaking solution for depression, addressing its unmet needs. Unlike conventional oral administration, our transdermal patch bypasses the gut and liver, eliminating the risk of food interactions that can impact effectiveness.


PIONEERING AI-DRIVEN DRUG DISCOVERY

Neurentis is at the forefront of innovation with our cutting-edge AI-driven drug discovery program, designed to revolutionise the treatment landscape for depression, including Treatment-Resistant Depression (TRD). Our collaboration with Netellis, a US-based biotech company specialising in artificial intelligence, allows us to leverage state-of-the-art computational power to accelerate the development of novel antidepressants.

Transforming Drug Discovery: Our AI-driven approach uses advanced virtual screening techniques to predict interactions between small molecules and target proteins/receptors. This method significantly accelerates the identification of promising drug candidates, streamlining the early stages of drug discovery while reducing costs and laboratory time.

Fueling the Future:

The Importance of External Innovation in Big Pharma's Pipeline

partnering licensing-business development pharma biotech company

The pharmaceutical industry is constantly evolving, with big pharmaceutical companies looking to enhance their product pipelines and stay ahead of the game. One of the ways they do this is through external innovation, in which they license drugs from smaller biotech companies like ours. In fact, it's estimated that anywhere from 30-40% of the drugs in the pipelines of big pharma companies come from external sources.

By partnering with innovative biotech firms, large companies can keep their pipelines filled with promising new treatments and stay at the forefront of the industry. By partnering with Neurentis, a company dedicated to developing novel drugs for neuropsychiatric diseases, big pharma companies as well as mid-size and regional players can access cutting-edge treatments and continue to push the boundaries of what's possible in healthcare.

read more